NR 519 Week 7 Chronic Illness Case Analysis Example

Chronic Illness Case Analysis: How the Lung's Repair Became Mr. L.'s Disease, and How Each Adaptation Along the Way Spent a Part of His Reserve

Student Name

College of Nursing, Chamberlain University

NR 519: Adv Nursing Practice Across the Health Continuum: Health Assessment, Pathophysiology, & Pharmacology

Instructor Name

Month Day, Year

Chronic Illness Case Analysis: How the Lung's Repair Became Mr. L.'s Disease, and How Each Adaptation Along the Way Spent a Part of His Reserve

The Case on a Chronic Timescale

Mr. L., now 67, was diagnosed with idiopathic pulmonary fibrosis two years ago. He was treated in hospital for an acute exacerbation four months ago and came home on continuous oxygen at 2 L/min at rest, rising to 4 L/min with activity. He continues nintedanib. His forced vital capacity has fallen from 68% of predicted at diagnosis to 57%. He walks about half the distance he managed two years ago, sleeps in a recliner and has lost 5 kg. This analysis looks at his illness on the timescale of years, asking how each change began as an adaptation that helped and became part of what now limits him.

Adaptation 1: Repair That Did Not Stop

The fibrosis itself began as repair. Current understanding holds that repeated small injuries to the alveolar lining trigger a wound-healing response in which fibroblasts are activated and lay down collagen to close the damage (Lederer & Martinez, 2018). In a healthy lung, that response ends when the lining is restored. In Mr. L.'s lung it did not end. Each round of repair added scar, and each scar replaced tissue that once exchanged gas. The adaptation that protected the lung from a single injury became, over years, the process that consumed it. Nintedanib slows that process but does not reverse it; in its trials, it reduced the rate of decline in lung function rather than restoring function already lost (Richeldi et al., 2014).

That distinction shapes what the medicine can be expected to do for him. It cannot give back the stairs he climbed two years ago; it can only make the loss of the next ones slower, and the analysis keeps that expectation explicit so that neither he nor his clinicians judge it by the wrong standard.

Adaptation 2: Rapid, Shallow Breathing

As his lungs stiffened, Mr. L. began to breathe faster and more shallowly, a pattern that reduces the work of stretching a stiff lung. For a long time it served him well, keeping carbon dioxide normal at low cost. On the chronic timescale it has a price. Shallow breaths ventilate proportionally more dead space, the airways that do not exchange gas, so each breath delivers less fresh air to the alveoli. And the respiratory muscles, working constantly at a high rate, have little reserve left when demand rises. When he caught a viral infection four months ago, there was nothing extra to give, and his breathing failed quickly into the exacerbation.

Adaptation 3: Narrowing the Blood Vessels in Poorly Ventilated Lung

When parts of his lung became poorly ventilated, the small arteries supplying them constricted, a normal response that sends blood toward better-ventilated regions and protects oxygen levels. When most of the lung is affected and low oxygen persists, that constriction becomes widespread and sustained, and scarring also destroys small vessels outright. Pressure in the pulmonary arteries rises. At diagnosis, Mr. L. had no signs of this. At his most recent visit, the second heart sound was louder over the pulmonic area and he had mild ankle swelling, early signs that the right ventricle is working against higher pressure. An adaptation that preserved his oxygen is now loading his heart.

Adaptation 4: Weight Loss and Less Activity

The effort of breathing raises energy use, while breathlessness while eating and nintedanib-related diarrhea reduce intake. He has lost 5 kg. Reduced activity lowers oxygen demand and so reduces breathlessness in the short term. Over months it weakens muscles, including the muscles of breathing, and makes each task harder when he does attempt it. Pulmonary rehabilitation was meant to counter this, rebuilding leg and arm strength so that ordinary tasks demanded less oxygen,, and it improved his exercise capacity for a time, as it does for many people with interstitial lung disease (Dowman et al., 2021). After the exacerbation, he did not return.

The Reserve, Counted

Put together, the analysis describes a man whose lung, breathing pattern, pulmonary circulation and muscles have each adapted to protect him and have each, in doing so, spent part of his reserve. The reserve left is small. A minor infection, a missed nintedanib dose, a hot day or a long walk now carries more risk than it did two years ago. This is the practical meaning of chronic illness for nursing care: the goal shifts from preventing the first problem to protecting the little reserve that remains.

Where the Timeline Could Have Run Differently

Looking back across two years shows points where the spending of reserve might have slowed. After the exacerbation, Mr. L. did not return to pulmonary rehabilitation, partly because the center was 40 minutes away and he now needed continuous oxygen for the drive. A home-based program or a closer center could have preserved some of the muscle he then lost. His weight loss was noted at two visits before anyone referred him to a dietitian. And his early signs of right heart strain were recorded but not yet discussed with him as a sign that his illness had entered a new phase. None of these would have stopped the fibrosis. Each might have left him with a little more reserve, and in a chronic illness with a small reserve, a little more can mean months, perhaps many months, of being able to walk to the mailbox, eat with his family and stay out of hospital. The analysis names them so that the next patient's timeline is watched for the same turning points.

What Nursing Care Protects Now

Four priorities follow. First, preventing infections that would use up his remaining reserve, through vaccination review and prompt attention to any fever or new sputum. Second, maintaining nutrition, with small frequent meals, oxygen during meals and management of diarrhea so he can keep taking nintedanib. Third, slowing the loss of muscle, with an adapted home exercise plan if he cannot return to rehabilitation. Fourth, watching for right heart strain, recording weight and ankle swelling at each visit, since fluid retention would add to his breathlessness. Alongside these, the care team should be honest with him that the underlying process continues. The guideline recognizes that disease course varies and that progression is common even with treatment (Raghu et al., 2022). That honesty is the ground for the next conversation, about what he wants from the time ahead.

References

Dowman, L., Hill, C. J., May, A., & Holland, A. E. (2021). Pulmonary rehabilitation for interstitial lung disease. Cochrane Database of Systematic Reviews, 2021(2), Article CD006322. https://doi.org/10.1002/14651858.CD006322.pub4

Lederer, D. J., & Martinez, F. J. (2018). Idiopathic pulmonary fibrosis. New England Journal of Medicine, 378(19), 1811-1823. https://doi.org/10.1056/NEJMra1705751

Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., Molina-Molina, M., Myers, J. L., Nicholson, A. G., Ryerson, C. J., Strek, M. E., Troy, L. K., Wijsenbeek, M., Mammen, M. J., Hossain, T., . . . Wilson, K. C. (2022). Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS/ALAT clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 205(9), e18-e47. https://doi.org/10.1164/rccm.202202-0399ST

Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., . . . Collard, H. R. (2014). Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. New England Journal of Medicine, 370(22), 2071-2082. https://doi.org/10.1056/NEJMoa1402584